Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity and TVR

25 May 2022 14:30

RNS Number : 8077M
DeepMatter Group PLC
25 May 2022
 

 

25 May 2022

 

Issue of Shares and Total Voting Rights

 

DeepMatter Group Plc (AIM: DMTR, "Deepmatter", the "Group"), the digital chemistry data and software company, announces as a result of the subscription to Ordinary Shares in the Company by Alan Aubrey, incoming Chair, application has been made for 200,000,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on or around 31 May 2022.

 

Following the subscription, Alan Aubrey will be interested in 207,311,393 Ordinary Shares which represents 5.17 per cent. of the issued share capital as enlarged by the subscription. The subscription price was 0.1 pence per Ordinary Share.

 

The new Ordinary Shares will rank pari passu with the existing shares of the Company. Following Admission, the Company's issued share capital will consist of 4,009,897,281 Ordinary Shares. Accordingly, the figure of 4,009,897,281 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For more information contact

 

DeepMatter Group Plc 0141 548 8156 Fraser Benson, Chief Financial Officer

Canaccord Genuity Limited (Nominated Advisor and Broker) 020 7523 8000Bobbie Hilliam

Meare Consulting 07990 858548Adrian Duffield

About DeepMatter Group plc 

 

DeepMatter's SmartChemistry™ platform enables scientists across a range of industries, including pharma, biotech, agri-science, scientific publishers and contract research organisations (CROs), to easily capture, access and exploit the vast amounts of data created in chemical reactions.

 

DeepMatter integrates its proprietary chemistry data and proprietary software to significantly improve productivity, efficiency, discovery, safety and sustainability of chemical reactions for its customers.

 

DeepMatter's SmartChemistry™ platform capitalises on the combination of its cloud technology, low cost-sensors, connectivity to laboratory hardware and high-performance computing trends such as artificial intelligence (AI).

 

Visit: www.deepmatter.io and follow @deepmattergroup

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESELFDIEESEFI
Date   Source Headline
22nd Mar 201910:39 amRNSHolding(s) in Company
20th Mar 20197:00 amRNSDirectors' Shareholdings
19th Mar 20194:52 pmRNSReplacement - Total Voting Rights and Notice of...
19th Mar 20193:35 pmRNSHolding(s) in Company
19th Mar 20193:32 pmRNSHolding(s) in Company
15th Mar 20198:10 amRNSTotal Voting Rights and Notice of Results
12th Mar 20197:00 amRNSGrant of Options
11th Mar 201912:58 pmRNSResult of Meeting & Directorate Change
7th Mar 20199:00 amRNSIssue of Equity
25th Feb 20197:00 amRNSAcquisition, Placing & Waiver of Rule 9
14th Feb 20193:58 pmRNSHolding(s) in Company
6th Feb 20194:42 pmRNSHolding(s) in Company
6th Feb 20194:41 pmRNSHolding(s) in Company
17th Jan 20197:00 amRNSDisposal of SICM business
20th Dec 20187:00 amRNSUpdate, Conditional Acquisition & Proposed Placing
30th Nov 20187:00 amRNSPublication of Paper in leading Journal
6th Sep 20183:06 pmRNSExercise of Options and Issue of Equity
6th Sep 20187:00 amRNSInterim Results
15th Aug 20187:00 amRNSFurther Pioneer Agreements and Notice of Results
19th Jul 20187:00 amRNSPublication of Scientific Paper
11th Jun 20187:00 amRNSDirectorate Changes
11th Jun 20187:00 amRNSIssue of Equity
16th May 201811:45 amRNSResult of AGM, name change and new website
24th Apr 20187:00 amRNSDirector Dealing
19th Apr 20187:00 amRNSSecond Pioneer Agreement Signed
12th Apr 20187:00 amRNSFirst Pioneer Agreement Signed
5th Apr 20183:28 pmRNSDirector Dealing
28th Mar 20187:00 amRNSFinal results for the year ended 31 December 2017
6th Feb 20187:00 amRNSMoUs signed with pioneers
19th Jan 20189:00 amRNSPublication of Scientific Paper
17th Jan 20187:00 amRNSPublication of Scientific Paper
6th Dec 20177:00 amRNSDirector Dealing
4th Dec 20177:00 amRNSNew Share Option Scheme and Grant to PDMR
1st Dec 20171:01 pmRNSDirectors' Dealing
28th Nov 20179:47 amRNSDirector Dealing
22nd Nov 20175:50 pmRNSHolding(s) in Company
20th Nov 201711:02 amRNSHolding(s) in Company
8th Nov 20178:11 amRNSCompletion of Acquisition, Appointment of Director
3rd Nov 20177:00 amRNSAcquisition of OpenIOLabs Limited
4th Oct 20177:00 amRNSChange of Adviser
12th Sep 20177:00 amRNSHalf-year Report
19th May 201711:34 amRNSResult of AGM
26th Apr 20177:00 amRNSDirectorate Changes
28th Mar 20177:00 amRNSFinal Results
16th Feb 20177:00 amRNSDigital Chemistry to be performed in space
31st Jan 20178:03 amRNSAdvisory Committee
31st Jan 20177:00 amRNSPresentation at Healthcare Conference
9th Jan 20177:00 amRNSDigitalGlasswareT
15th Sep 20167:00 amRNSHalf-year Report
12th May 201611:45 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.